Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet

Vaccine candidate was generally well tolerated, meeting the study’s primary objective of safety Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with BCG LONDON--(BUSINESS WIRE)--Feb. 4, 2013-- Data were published in The Lancet today from a Phase IIb clinical trial evaluating the safety and efficacy of MVA85A in preventing tuberculosis (TB) in infants. MVA85A is a TB vaccine candidate designed to boost immune responses already primed by the Bacille Calmette-Guérin (BCG) vaccine, the ...